Inozyme Pharma, Inc. (INZY) - רווח נקי למניה (EPS TTM)

Anticipation of the Phase 2 trial results for the treatment of vascular calcification serves as the primary driver for Inozyme Pharma, Inc. (INZY), while current expenditures are already priced in. The development of enzyme-based therapies for rare mineralization pathologies ensures monopoly demand. The lifelong therapy cycle guarantees the business a stable cash flow. Net income per share over 12 months visualizes the capital, where the -1.69 level records the latest values.

The market value of Inozyme Pharma, Inc. (INZY) depends directly on capital management efficiency, as reflected by net earnings per share. This metric is calculated by dividing total annual income by the number of securities, which clearly demonstrates the change in TTM net income per share. The stability of this indicator confirms the resilience of the business. For a pharmaceutical company providing lifelong patient treatment, such dynamics guarantee long-term profitability. It is critical for investors to monitor this trend to eliminate the risk of asset overvaluation.